Regulation of vitamin K-dependent carboxylation.
Vitamin K-dependent carboxylation activity measured with pentapeptide substrate (Phe-Leu-Glu-Glu-Leu) gradually decreases upon in vivo injection of vitamin K to vitamin K-deficient rats. A decrease in pentapeptide carboxylation can also be observed by the in vitro addition of antibodies against prothrombin and other vitamin K-dependent proteins to the soluble system derived from vitamin K-deficient rat liver microsomes. In both cases, adding back in vitro partially decarboxylated vitamin K-dependent proteins or purified hepatic prothrombin precursor restores the level of pentapeptide carboxylation. After warfarin treatment, a 3-fold increase in carboxylation results, which can be abolished by giving cycloheximide along with the warfarin. However, the resulting decreased activity is restored by the in vitro addition of partially decarboxylated vitamin K-dependent proteins. These data are consistent with the hypothesis that (after warfarin treatment) increased peptide carboxylation is primarily due to activation of the system by precursor proteins, rather than synthesis of an increased amount of enzyme.
D000818:Animals; D000937:Antigen-Antibody Reactions; D002245:Carbon Dioxide / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D007020:Hypoprothrombinemias / Q000378:metabolism*; D007106:Immune Sera; D007700:Kinetics; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism*; D009842:Oligopeptides / Q000378:metabolism; D011506:Proteins / Q000378:metabolism*; D011516:Prothrombin / Q000096:biosynthesis*; D051381:Rats; D014812:Vitamin K / Q000494:pharmacology; D014813:Vitamin K Deficiency / Q000378:metabolism*; D014859:Warfarin
D007106:Immune Sera; D009842:Oligopeptides; D011506:Proteins; D014812:Vitamin K; D002245:Carbon Dioxide; D014859:Warfarin; D011516:Prothrombin; D003513:Cycloheximide